Those CYP2D6 extensive metabolizers (EMs) who harbor an APOE-4/4 genotype are poor responders to conventional treatments, reflecting the negative influence that the APOE-4 allele exerts on the pharmacogenetic outcome in AD patients [6,10,16,17,24,25,26]. This evidence concerns the gene APOE and Alzheimer disease.